Biogen Reveals Positive Result For Phase 3 Trial Of Zinbryta In MS Patients

(RTTNews) - Biogen (BIIB) and AbbVie (ABBV) said the pivotal 'Decide' study showed a significantly greater number of people treated with Zinbryta achieved no evidence of disease activity compared to those treated with Avonex intramuscular injection. Additional new interim data from the long-term extension study, Extend, further affirmed its efficacy on clinically meaningful measures of multiple sclerosis disease activity and provide additional information supporting Zinbryta's safety profile.

Decide was a two- to three-year, Phase 3, global, randomized, double-blind, multicenter study, using Zinbryta, a once-monthly, self-administered, subcutaneous treatment option for people living with relapsing forms of Multiple Sclerosis or MS. It is approved for the treatment of relapsing forms of multiple sclerosis in the United States and the European Union.

Ralph Kern, senior vice president, Worldwide Medical, Biogen said, "These data continue to reinforce Zinbryta's robust efficacy in reducing MS relapse rates, disability progression and brain lesion development, and help further define its long-term safety profile."